Keep eyes open for this!
$Dare Bioscience(DARE.US$ Daré is continuing to interact with the FDA as the FDA reviews, specifically, the data generated on the proposed endpoints to take forward into Phase 3 development. The FDA has indicated it anticipates providing additional feedback on the Phase 3 design in 2Q-2024.
Daré's planned Phase 3 study of Sildenafil Cream, 3.6% would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. Daré intends to provide updates on the FDA feedback, Phase 3 study design and plans, as well as any relevant updates on its collaboration strategy as available in 2024.
Daré's planned Phase 3 study of Sildenafil Cream, 3.6% would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. Daré intends to provide updates on the FDA feedback, Phase 3 study design and plans, as well as any relevant updates on its collaboration strategy as available in 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Gman511 : Ty
Gman511 :
Gman511 : Load OCGN before it’s too late
!!!
Gman511 :
OCGN 
TrytosaveabitOP Gman511: Thanks! But I still don’t believe it’s hit bottom?
Gman511 : Going up up up
Gman511 :
TrytosaveabitOP Gman511: Ok then! GL and big profits to ya!
Gman511 : Perfect entry now!!!
Gman511 : Moneybags!!!
View more comments...